AI in Medicine — Cancer & Rare Disease — 2026-09-29 (Tue) Evening News

Latest news on AI and cancer treatment

Overview

There is movement in diagnostics (expanding the practical use of breast cancer AI screening), regulations (FDA item clearance for Tempus AI), and drug discovery (AbbVie's AI drug discovery partnership). A statistical analysis of clinical trials (a review of 195 trials) was also reported, but there was no primary information showing the registration status of individual trials.

Breast cancer

It has been reported that South Korea's Lunit's breast cancer screening support AI will be used in the Stockholm area to assist in the co-reading of 250,000 mammography images a year. The target is a screening program for local residents, and quantitative results such as accuracy and detection rate are not listed in the headline. Additionally, there are reports that GEHC (GE Healthcare) and Mass General Brigham (MGB) are partnering to apply generative AI to radiation therapy (details are unknown). In Luxembourg, there was an article pointing out that the introduction of AI into hospitals is progressing without a national inventory control (central ledger), and this is cited as a governance issue for the introduction of AI, not only in the field of breast cancer.

lung cancer

No applicable information

Malignant brain tumor

No relevant information regarding clinical/research reports. In a related headline, there is a report that newscaster Sheinelle Jones said about the AI interview video that her children underwent after her husband's death, "It didn't actually happen (false)," but this is not about medical content about cancer treatment or brain tumors, but general news about AI deep fakes.

Leukemia/lymphoma

Onco'Zine publishes an article analyzing 195 clinical trials related to AI in oncology. It is unclear from the headline whether the content is specific to hematological tumors, and details such as target cancer types, phases, and registration status are not listed.

Colon cancer/digestive organ

The CDOTrends article ``The AI Is in the Scope. The Evidence Isn't.'' appears to be an article arguing that ``there is no evidence'' regarding endoscopic AI (polyp detection support, etc.), but the headline alone does not include specific test names or numerical values. Avoid making definitive statements about effectiveness, detection rate, etc.

Rare cancer

The headline that was categorized as related to adenoid cystic carcinoma was that UK DYAD raised US$10 million to expand its medical AI business and deploy it for the NHS. A direct relationship with adenoid cystic carcinoma cannot be confirmed from the headline, and the correspondence relationship is unknown.

Diagnosis/Pathology/Image

An Indian news article discusses the possibilities and challenges of "biomarkers identified by AI," but the target cancer type, measurement target, and verification stage are not mentioned in the headline. Onco'Zine's "Artificial intelligence in Oncology: Where Promise Meets Reality" is also seen as a review article that deals with the current state and challenges of AI in oncology in general.

Treatment selection/drug discovery

AbbVie has partnered with biotech company Iambic, which is preparing for an IPO, on drug discovery using AI. The stage is considered to be the "discovery" stage, and is presumed to be in the early pre-clinical stage, but there is no information on the target disease, compound, or phase in the heading.

Regulations/Approval

- Tempus AI: Reported to have obtained FDA clearance (distinguished from 510(k) clearance and approval) for ECG-MR (which appears to be a test/algorithm that combines electrocardiogram and MRI). Direct indications for cancer oncology are unclear from the headline. - South Korea's SM Entertainment has filed a criminal complaint against its artist Im Yoona for creating deepfake images. General AI regulation news unrelated to medical care and cancer treatment.

Clinical trial implementation status

Regarding the individual trial name, target cancer type, phase, and registration status from ClinicalTrials.gov, the information provided this time does not include specific trial data. We do not make assumptions about the number of cases or registration status.

Japanese movements

crisp_bio publishes an article about building a "virtual biotech". The content is about a multi-agent AI framework that operates under human instructions, and appears to be a topic related to drug discovery research infrastructure, but there is no mention of direct application to cancer treatment or clinical stages in the heading.

Remarks from VIPs

The list of important people to be tracked is blank, so there is no relevant speech information.

Note: This report is based on the headline information provided and does not reference the text of the article or primary data from ClinicalTrials.gov. In particular, there is little information on the items ``rare cancer,'' ``clinical trial implementation status,'' and ``lung cancer,'' so it is necessary to check for follow-up reports.

Latest news on AI and rare and incurable diseases

Overview

There was one case report using AI in the rare disease diagnosis field, and two cases in the genetic analysis field. There are no headings regarding therapeutic drug development or institutional aspects.

Diagnosis of rare diseases

The BBC reported that AI helped diagnose a daughter's rare disease. The specific disease name, diagnosis rate, and shortening period are not listed in the headline, and the content appears to be based on the experiences of individual families. This is a case-by-case report and does not indicate statistical effects.

Gene analysis/genome

- Medical Xpress reported that experiments using AI and fruit flies have linked the BRSK1 gene to a rare neurodevelopmental disorder. The research is at the preclinical (model organism) stage, and the verification stage in humans cannot be confirmed from the headline. Whether the disease in question falls under the list of 348 incurable diseases designated by the Ministry of Health, Labor and Welfare cannot be confirmed just from the information in the heading. The specific operational status of the platform and its track record of application to rare diseases are not mentioned in the headline, so it is not possible to judge the details.

Development of therapeutic drugs

No applicable information

Nerve/muscular diseases

Medical Xpress's BRSK1-related report mentions neurodevelopmental disorders, but this is a study on developmental disorders in children, and does not match the names of diseases in the "neuro-muscular diseases" group (87 cases, including spinal and bulbar muscular atrophy and amyotrophic lateral sclerosis). It is not possible to confirm whether it is a designated intractable disease or not.

Immunology/Collagen disease

No applicable information

Rare metabolic/endocrine diseases

No applicable information

System/Patient Support

No applicable information

Japanese movements

No applicable information

Remarks from VIPs

No applicable information